Leveraging the immune system to treat advanced thyroid cancers

Jena D. French, Keith Bible, Christine Spitzweg, Bryan R. Haugen, Mabel Ryder

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


Inflammation has long been associated with the thyroid and with thyroid cancers, raising seminal questions about the role of the immune system in the pathogenesis of advanced thyroid cancers. With a growing understanding of dynamic tumour-immune cell interactions and the mechanisms by which tumour cells evade antitumour immunity, the field of cancer immunotherapy has been revolutionised. In this Review, we provide evidence to support the presence of an antitumour immune response in advanced thyroid cancers linked to cytotoxic T cells and NK cells. This antitumour response, however, is likely blunted by the presence of immunosuppressive pathways within the microenvironment, facilitated by tumour-associated macrophages or increased expression of negative regulators of cytotoxic T-cell function. Current and future efforts to incorporate immune-based therapies into existing tumour cell or endothelial-derived therapies—eg, with kinase inhibitors targeting tumour-associated macrophages or antibodies blocking negative regulators on T cells—could provide improved and durable responses for patients with disease that is otherwise refractory to treatment.

Original languageEnglish (US)
Pages (from-to)469-481
Number of pages13
JournalThe Lancet Diabetes and Endocrinology
Issue number6
StatePublished - Jun 2017

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Leveraging the immune system to treat advanced thyroid cancers'. Together they form a unique fingerprint.

Cite this